Enoxaparin (Lovenox) adjust dose for severe renal impairment
August 17, 2004
A dosage adjustment is required in patients with severe renal impairment (creatinine clearance <30 mL/min) who have increased exposure to enoxaparin. Patients with severe renal impairment should receive enoxaparin (Lovenox) 30 mg subcutaneously once daily or 1 mg/kg subcutaneously once daily, depending on indication. Adjustments are not required for patients with mild or moderate renal impairment. Dosage adjustments are also not required in low-weight patients (< 45 kg for women and < 57 kg for men), but observe these patients carefully for signs and symptoms of bleeding. Aventis sent a warning letter in March 2004, and has just recently updated their product labeling. The FDA has issued a MedWatch safety alert regarding this labeling change.
More information is available at the following links:
- MedWatch Alert:
- Dear Healthcare Professional Letter:
- Revised Product Label:
August 17, 2004; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.